Clinical Trials Directory

Trials / Unknown

UnknownNCT02689037

Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis

Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis: Study Protocol of a Randomized Controlled Trial

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
394 (estimated)
Sponsor
The 476th Hospital of People's Liberation Army · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Background: Effectiveness of Percutaneous transluminal angioplasty and stenting (PTAS) on prevention of events of stroke and death in patients with symptomatic intracranial atherosclerosis (ICAS) is controversial. Aim: to determine whether PTAS plus medical treatment (MT) are superior to MT alone in preventing events of stroke and death in patients with symptomatic ICAS. Methods: The investigators will carry out a randomized controlled trial in 3 hospitals in China. A total of 198 patients with ICAS will be randomized into 2 groups: PTAS+MT and MT group. All patients will receive aspirin (100 mg daily) and clopidogrel (75 mg daily) immediately after randomization, and patients in PTAS+MT group will receive surgery within 5 days after randomization. The patients will be followed up for 1 year after randomization and assessed for events of stroke and death at 30 days and 1 year after randomization, the incidence of recurrent ischaemic stroke in the stenting-involved vascular territory at 30 days and 1 year after randomization, incidence of in-stent restenosis at 1 year after randomization,etc.

Conditions

Interventions

TypeNameDescription
PROCEDUREPercutaneous transluminal angioplasty and stentingSurgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
DRUGAspirin plus clopidogrelaspirin 100mg daily and clopidogrel 75mg daily for 90 days

Timeline

Start date
2016-04-01
Primary completion
2018-12-01
Completion
2019-12-01
First posted
2016-02-23
Last updated
2016-04-05

Source: ClinicalTrials.gov record NCT02689037. Inclusion in this directory is not an endorsement.